NEW YORK (GenomeWeb) – OncoCyte reported after the close of the market on Tuesday that its third quarter net loss more than doubled amid higher operating expenses.

The company also disclosed a delay in the planned commercial launch of its first product, the liquid biopsy lung cancer diagnostic DetermaVu, due to technical issues during a clinical validation study.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Dec
04
Sponsored by
Sophia Genetics

This webinar will discuss the use of clinical-grade exome analysis application in complex case investigations.

Dec
12

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.